Skip to content
lifestyle.bossesmag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Replimune, Inc.
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
June 1, 2026
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
June 1, 2026
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
June 1, 2026
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2026
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
February 3, 2026